Dosing vs Assessment Intervals With Faricimab and Aflibercept-Reference-Cited by-同舟云学术

Dosing vs Assessment Intervals With Faricimab and Aflibercept

Published:2024-08-01 Issue:8 Volume:142 Page:697
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Freund K. Bailey¹²,Bijon Jacques¹²,Ramtohul Prithvi¹³

Affiliation:

1. Vitreous Retina Macula Consultants of New York, New York

2. Department of Ophthalmology, New York University Grossman School of Medicine, New York

3. Department of Ophthalmology, Hôpital Nord, University Aix-Marseille, Marseille, France

Abstract

This Viewpoint highlights the discrepancy between dosing and patient assessment schedules in clinical trials for 2 new intravitreal agents, faricimab, 6 mg, and aflibercept, 8 mg, to treat neovascular age-related macular degeneration.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2820323/jamaophthalmology_freund_2024_vp_240002_1723584449.98477.pdf

Reference7 articles.

1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.;Heier;Lancet,2022

2. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.;Martin;Ophthalmology,2012

3. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.;Ho;Ophthalmology,2014

4. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial.;Wells;Ophthalmology,2016